Europeiska unionen - isländska - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - stækkun Æxli, gelding-Þola - heilsueyðandi lyf - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - valsartanum inn - mixtúra, lausn - 3 mg/ml

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 600 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 300 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 150 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - deferoxaminum mesýlat - stungulyfs-/innrennslisstofn, lausn - 500 mg